Chen Haoran, Qi Xiaofen, Guan Kaifang, Wang Rongchun, Li Qiming, Ma Ying
School of Chemistry and Chemical Engineering, Harbin Institute of Technology, Harbin, 150001, Heilongjiang, China.
New Hope Dairy Co. Ltd., Chengdu, 610063, Sichuan, China; Dairy Nutrition and Function, Key Laboratory of Sichuan Province, Chengdu, 610000, Sichuan, China.
J Dairy Sci. 2023 Apr;106(4):2271-2288. doi: 10.3168/jds.2022-22511. Epub 2023 Feb 14.
The objective of this study was to investigate the mechanism by which the α-lactalbumin peptides Gly-Ile-Asn-Tyr (GINY) and Asp-Gln-Trp (DQW) ameliorate free fatty acid-induced lipid deposition in HepG2 cells. The results show that GINY and DQW reduced triglyceride, total cholesterol, and free fatty acid levels significantly in free fatty acid-treated HepG2 cells. Based on proteomic analysis, GINY and DQW alleviated lipid deposition and oxidative stress mainly through the peroxisome proliferator-activated receptor (PPAR) pathway, fatty acid metabolism, oxidative phosphorylation, and response to oxidative stress. In vitro experiments confirmed that GINY and DQW upregulated the mRNA and protein expression of fatty acid β-oxidation-related and oxidative stress-related genes, and downregulated the mRNA and protein expression of lipogenesis-related genes by activating peroxisome proliferator-activated receptor α (PPARα). Meanwhile, GINY and DQW reduced free fatty acid-induced lipid droplet accumulation and reactive oxygen species generation, and enhanced the mitochondrial membrane potential and ATP levels. Furthermore, GINY and DQW enhanced carnitine palmitoyl-transferase 1a (CPT-1a) and superoxide dismutase activities, and diminished acetyl-coenzyme A carboxylase 1 (ACC1) and fatty acid synthase (FASN) activities in a PPARα-dependent manner. Interestingly, GW6471 (a PPARα inhibitor) weakened the effects of GINY and DQW on the PPARα pathway. Hence, our findings suggest that GINY and DQW have the potential to alleviate nonalcoholic fatty liver disease by activating the PPARα pathway.
本研究的目的是探究α-乳白蛋白肽Gly-Ile-Asn-Tyr(GINY)和Asp-Gln-Trp(DQW)改善游离脂肪酸诱导的HepG2细胞脂质沉积的机制。结果表明,GINY和DQW显著降低了游离脂肪酸处理的HepG2细胞中的甘油三酯、总胆固醇和游离脂肪酸水平。基于蛋白质组学分析,GINY和DQW主要通过过氧化物酶体增殖物激活受体(PPAR)途径、脂肪酸代谢、氧化磷酸化以及对氧化应激的反应来减轻脂质沉积和氧化应激。体外实验证实,GINY和DQW通过激活过氧化物酶体增殖物激活受体α(PPARα)上调脂肪酸β-氧化相关基因和氧化应激相关基因的mRNA和蛋白质表达,并下调脂肪生成相关基因的mRNA和蛋白质表达。同时,GINY和DQW减少了游离脂肪酸诱导的脂滴积累和活性氧生成,并增强了线粒体膜电位和ATP水平。此外,GINY和DQW以PPARα依赖的方式增强了肉碱棕榈酰转移酶1a(CPT-1a)和超氧化物歧化酶的活性,并降低了乙酰辅酶A羧化酶1(ACC1)和脂肪酸合酶(FASN)的活性。有趣的是,GW6471(一种PPARα抑制剂)削弱了GINY和DQW对PPARα途径的作用。因此,我们的研究结果表明,GINY和DQW具有通过激活PPARα途径缓解非酒精性脂肪性肝病的潜力。